Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist prescribed for the management of type 2 diabetes mellitus. It helps regulate blood sugar levels by stimulating insulin secretion, reducing glucagon release, and slowing gastric emptying. Administered as a once-weekly subcutaneous injection, Ozempic supports improved glycemic control in adults when combined with diet and exercise. It may also promote weight loss and has been shown to reduce the risk of major cardiovascular events in patients with type 2 diabetes and established heart disease. Patients should follow healthcare provider guidance for dosage and administration. Possible side effects include nausea, vomiting, diarrhea, and risk of pancreatitis.